Federal lawmakers are exploring ways to improve prescription drug affordability for patients. Biosimilars are innovative treatments that have the potential to save patients and taxpayers alike billions in healthcare costs.
But members of Congress have failed to act to expand access to these treatments for patients who need them most. We need policymakers to provide a pathway to make more affordable biosimilar treatments for chronic and complex conditions available.
Send a letter to your Representative TODAY: Tell Congress to expand access to safe, affordable, and effective biosimilars now.
Every day, people with chronic and complex conditions are making difficult choices to make ends meet.
The lack of access to safe and effective biosimilar drugs that provide cost advantages over other therapies unnecessarily increases the financial burden on many of the most vulnerable members of our society. According to some estimates, biosimilar drugs currently on the market could save the U.S. as much as $54 billion over the next decade.
You and your colleagues in Congress have the power to change that by easing restrictions that block these affordable drugs from reaching patients.
Expanding access to biosimilars can open up market competition in the healthcare industry, potentially drive down healthcare costs, and reduce out-of-pocket costs for patients who need them most.
As a concerned constituent, I'm asking you to do something about this. We cannot wait any longer. I urge you to take the lead in passing legislation to open access to biosimilar products. Save patients and taxpayers alike billions.
Thank you for your consideration.